Patents by Inventor Peter Sazani

Peter Sazani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20210180060
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: June 12, 2020
    Publication date: June 17, 2021
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Peter SAZANI, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20190284556
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: September 28, 2018
    Publication date: September 19, 2019
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20190127738
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 2, 2019
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Peter SAZANI, Ryszard KOLE
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20180066259
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: October 20, 2017
    Publication date: March 8, 2018
    Inventors: Peter SAZANI, Ryszard KOLE
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20170292125
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: November 11, 2016
    Publication date: October 12, 2017
    Inventors: Peter SAZANI, Ryszard KOLE
  • Multiple exon skipping compositions for DMD
    Patent number: 9453225
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: September 27, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • Multiple exon skipping compositions for DMD
    Patent number: 9447416
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: September 20, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • Multiple exon skipping compositions for DMD
    Patent number: 9447417
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: September 20, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • Multiple exon skipping compositions for DMD
    Patent number: 9434948
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 6, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • Multiple exon skipping compositions for DMD
    Patent number: 9234198
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 12, 2016
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20160002633
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20160002634
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20160002637
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20150376618
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20150376617
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: PETER SAZANI, RYSZARD KOLE
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20150152415
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: October 24, 2014
    Publication date: June 4, 2015
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter SAZANI, Ryszard KOLE
  • Multiple exon skipping compositions for DMD
    Patent number: 8871918
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: October 28, 2014
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • Multiple exon skipping compositions for DMD
    Patent number: 8865883
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 21, 2014
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Sazani, Ryszard Kole
  • MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
    Publication number: 20140094500
    Abstract: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 3, 2014
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter SAZANI, Ryszard KOLE
  • Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
    Patent number: 7884194
    Abstract: Soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with HER2 and HER3 antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids, are provided for treatment of proliferative diseases, in particular cancer. Also provided are compositions and methods for inducing expression of these splice variants, including splice switching oligonucleotides that modulate splicing of pre-mRNA that codes for these receptors.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 8, 2011
    Assignee: AVI BioPharma Inc.
    Inventors: Ryszard Kole, Peter Sazani, Jing Wan